Regulation of ubiquitin-proteasome and autophagy pathways after acute LPS and epoxomicin administration in mice

BMC Musculoskeletal Disorders

Marc Francaux¹  Jean-Marc Raymackers¹  Louise Deldicque²  Shannamar Dewey³  Aldrin V Gomes³  Cécile Jamart¹ 

[1]Institute of Neuroscience, Université catholique de Louvain, Place Pierre de Coubertin, 1 bte L8.10.01, Louvain-la-Neuve 1348, Belgium

[2]Exercise Physiology Research Group, Department of Kinesiology, KU Leuven, Leuven B-3001, Belgium

[3]Department of Neurobiology, Physiology & Behavior, University of California, Davis, CA 95616, USA

关键词: Proteasome inhibitors;    Endotoxemia;    LC3;    MAFbx;    MuRF1;   

Others  :  1125716
DOI  :  10.1186/1471-2474-15-166

 received in 2014-01-17, accepted in 2014-05-13,  发布年份 2014

【 摘 要 】

Background

The ubiquitin-proteasome pathway (UPP) is a major protein degradation pathway that is activated during sepsis and has been proposed as a therapeutic target for preventing skeletal muscle loss due to cachexia. Although several studies have investigated the modulation of proteasome activity in response to LPS administration, none have characterized the overall UPP response to LPS administration in the fate of proteasome inhibition.

Methods

Here, we determined the modulation pattern of the main key components of the UPP in the gastrocnemius (GAS) of mice during the acute phase of lipopolysaccharide (LPS)-mediated endotoxemia (7.5 mg/kg – 8 h) by measuring all three β1, β2 and β5 activites of the 20S and 26S proteasomes, the levels of steady state polyubiquitinated proteins, mRNA levels of muscle ligases, as well as signaling pathways regulating the UPP. Another goal was to assess the effects of administration of a specific proteasome inhibitor (epoxomicin, 0.5 mg/kg) on UPP response to sepsis.

Results

The acute phase of LPS-induced endotoxemia lowered GAS/body weight ratio and increased MuRF1 and MAFbx mRNA concomitantly to an activation of the pathways known to regulate their expression. Unexpectedly, we observed a decrease in all 20S and 26S proteasome activities measured in GAS, which might be related to oxidative stress, as oxidized proteins (carbonyl levels) increase with LPS. While significantly inhibiting 20S and 26S proteasome β5 activities in heart and liver, epoxomicin did not lower proteasome activity in GAS. However, the increase in mRNA expression of the muscle ligases MuRF1 and MAFbx were partially rescued without affecting the other investigated signaling pathways. LPS also strongly activated autophagy, which could explain the observed GAS atrophy with LPS-induced reduction of proteasome activity.

Conclusions

Our results highlight an opposite regulation of UPP in the early hours of LPS-induced muscle atrophy by showing reduced proteasome activities and increased mRNA expression of muscle specific ligases. Furthermore, our data do not support any preventive effect of epoxomicin in muscle atrophy due to acute cachexia since proteasome activities are not further repressed.

【 授权许可】

   
2014 Jamart et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Evans WJ: Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr 2010, 91:1123S-1127S.
• [2]Hasselgren PO, Talamini M, James JH, Fischer JE: Protein metabolism in different types of skeletal muscle during early and late sepsis in rats. Arch Surg 1986, 121:918-923.
• [3]Brun J, Gray DA: Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients. Crit Care 2009, 13:311. BioMed Central Full Text
• [4]Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
• [5]Doi K, Leelahavanichkul A, Yuen PS, Star RA: Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009, 119:2868-2878.
• [6]Lang CH, Frost RA, Bronson SK, Lynch CJ, Vary TC: Skeletal muscle protein balance in mTOR heterozygous mice in response to inflammation and leucine. Am J Physiol Endocrinol Metab 2010, 298:E1283-E1294.
• [7]Dehoux MJ, van Beneden RP, Fernandez-Celemin L, Lause PL, Thissen JP: Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 2003, 544:214-217.
• [8]Fagan JM, Waxman L, Goldberg AL: Red blood cells contain a pathway for the degradation of oxidant-damaged hemoglobin that does not require ATP or ubiquitin. J Biol Chem 1986, 261:5705-5713.
• [9]Davies KJ, Goldberg AL: Proteins damaged by oxygen radicals are rapidly degraded in extracts of red blood cells. J Biol Chem 1987, 262:8227-8234.
• [10]Asher G, Bercovich Z, Tsvetkov P, Shaul Y, Kahana C: 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 2005, 17:645-655.
• [11]Asher G, Tsvetkov P, Kahana C, Shaul Y: A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 2005, 19:316-321.
• [12]Kisselev AF, Akopian TN, Castillo V, Goldberg AL: Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol Cell 1999, 4:395-402.
• [13]Safranek R, Ishibashi N, Oka Y, Ozasa H, Shirouzu K, Holecek M: Modulation of inflammatory response in sepsis by proteasome inhibition. Int J Exp Pathol 2006, 87:369-372.
• [14]Reis J, Tan X, Yang R, Rockwell CE, Papasian CJ, Vogel SN, Morrison DC, Qureshi AA, Qureshi N: A combination of proteasome inhibitors and antibiotics prevents lethality in a septic shock model. Innate Immun 2008, 14:319-329.
• [15]Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
• [16]Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 1999, 96:10403-10408.
• [17]Kovarik M, Muthny T, Sispera L, Holecek M: Effects of beta-hydroxy-beta-methylbutyrate treatment in different types of skeletal muscle of intact and septic rats. J Physiol Biochem 2010, 66:311-319.
• [18]Supinski GS, Vanags J, Callahan LA: Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction. Am J Physiol Lung Cell Mol Physiol 2009, 296:L994-L1001.
• [19]Vesali RF, Cibicek N, Jakobsson T, Klaude M, Wernerman J, Rooyackers O: Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers. Clin Sci (Lond) 2010, 118:421-427.
• [20]Kovarik M, Muthny T, Sispera L, Holecek M: The dose-dependent effects of endotoxin on protein metabolism in two types of rat skeletal muscle. J Physiol Biochem 2012, 68:385-395.
• [21]Doyle A, Zhang G, Abdel Fattah EA, Eissa NT, Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J: Offic Publ Fed Am Soc Exp Biol 2011, 25:99-110.
• [22]Mofarrahi M, Sigala I, Guo Y, Godin R, Davis EC, Petrof B, Sandri M, Burelle Y, Hussain SN: Autophagy and skeletal muscles in sepsis. PLoS One 2012, 7:e47265.
• [23]Schakman O, Dehoux M, Bouchuari S, Delaere S, Lause P, Decroly N, Shoelson SE, Thissen JP: Role of IGF-I and the TNFalpha/NF-kappaB pathway in the induction of muscle atrogenes by acute inflammation. Am J Physiol Endocrinol Metab 2012, 303:E729-E739.
• [24]Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD: Cachexia: a new definition. Clin Nutr 2008, 27:793-799.
• [25]Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ: Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001, 294:1704-1708.
• [26]Gilda JE, Gomes AV: Stain-Free total protein staining is a superior loading control to beta-actin for Western blots. Anal Biochem 2013, 440:186-188.
• [27]Gomes AV, Waddell DS, Siu R, Stein M, Dewey S, Furlow JD, Bodine SC: Upregulation of proteasome activity in muscle RING finger 1-null mice following denervation. FASEB J: Offic Publ Fed Am Soc Exp Biol 2012, 26:2986-2999.
• [28]Cui Z, Gilda JE, Gomes AV: Crude and purified proteasome activity assays are affected by type of microplate. Anal Biochem 2014, 446:44-52.
• [29]Gomes AV, Young GW, Wang Y, Zong C, Eghbali M, Drews O, Lu H, Stefani E, Ping P: Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues. Mol Cell Proteomics 2009, 8:302-315.
• [30]Gomes AV, Zong C, Edmondson RD, Li X, Stefani E, Zhang J, Jones RC, Thyparambil S, Wang GW, Qiao X, Bardag-Gorce F, Ping P: Mapping the murine cardiac 26S proteasome complexes. Circ Res 2006, 99:362-371.
• [31]Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034.
• [32]Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403.
• [33]Sandri M: Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008, 23:160-170.
• [34]Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
• [35]Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cersosimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N: Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008, 57:2595-2602.
• [36]Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
• [37]Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, Reid MB: TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J: Offic Publ Fed Am Soc Exp Biol 2005, 19:362-370.
• [38]Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, Azuma J: Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 2008, 79:89-96.
• [39]Jin B, Li YP: Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. J Cell Biochem 2007, 100:960-969.
• [40]Rodgers KJ, Dean RT: Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003, 35:716-727.
• [41]Ishii T, Sakurai T, Usami H, Uchida K: Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 S proteasome. Biochemistry 2005, 44:13893-13901.
• [42]Barth S, Glick D, Macleod KF: Autophagy: assays and artifacts. J Pathol 2010, 221:117-124.
• [43]Klionsky DJ: Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007, 8:931-937.
• [44]Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T: Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 2009, 452:181-197.
• [45]Mizushima N, Yoshimori T: How to interpret LC3 immunoblotting. Autophagy 2007, 3:542-545.
• [46]Iorga A, Dewey S, Partow-Navid R, Gomes AV, Eghbali M: Pregnancy is associated with decreased cardiac proteasome activity and oxidative stress in mice. PLoS One 2012, 7:e48601.
• [47]Vanasco V, Magnani ND, Cimolai MC, Valdez LB, Evelson P, Boveris A, Alvarez S: Endotoxemia impairs heart mitochondrial function by decreasing electron transfer, ATP synthesis and ATP content without affecting membrane potential. J Bioenerg Biomembr 2012, 44:243-252.
• [48]Bar-Nun S, Glickman MH: Proteasomal AAA-ATPases: Structure and function. Biochim Biophys Acta 1823, 2012:67-82.
• [49]Tawa NE Jr, Odessey R, Goldberg AL: Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997, 100:197-203.
• [50]Lukas G, Brindle SD, Greengard P: The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971, 178:562-564.
• [51]Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
• [52]Jamart C, Raymackers JM, Li An G, Deldicque L, Francaux M: Prevention of muscle disuse atrophy by MG132 proteasome inhibitor. Muscle Nerve 2011, 43:708-716.
• [53]Caron AZ, Haroun S, Leblanc E, Trensz F, Guindi C, Amrani A, Grenier G: The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC Musculoskelet Disord 2011, 12:185. BioMed Central Full Text
• [54]Zhao J, Brault JJ, Schild A, Goldberg AL: Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 2008, 4:378-380.
• [55]Chen GQ, Mou CY, Yang YQ, Wang S, Zhao ZW: Exercise training has beneficial anti-atrophy effects by inhibiting oxidative stress-induced MuRF1 upregulation in rats with diabetes. Life Sci 2011, 89:44-49.